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Development of Clinical Criteria for 
Functional Assessment to Predict Primary 
Nonfunction of High-Risk Livers Using 
Normothermic Machine Perfusion
Hynek Mergental,1,2* Barnaby T. F. Stephenson,1* Richard W. Laing,1,2* Amanda J. Kirkham,3* 
Desley A. H. Neil,2* Lorraine L. Wallace,1 Yuri L. Boteon,1,2 Jeannette Widmer ,1  
Ricky H. Bhogal,1,2 M. Thamara P. R. Perera,2 Amanda Smith,2 Gary M. Reynolds,1  
Christina Yap,3 Stefan G. Hübscher,1 Darius F. Mirza,1,2 and Simon C. Afford1*
1National Institute for Health Research Birmingham, Liver Biomedical Research Centre, College of Medical and Dental Sciences, 
University of  Birmingham; 2Liver Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham National Health 
Service Foundation Trust; and 3Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomics Sciences, University of 
Birmingham, Birmingham, United Kingdom
Increased use of high-risk allografts is critical to meet the demand for liver transplantation. We aimed to identify criteria pre-
dicting viability of organs, currently declined for clinical transplantation, using functional assessment during normothermic 
machine perfusion (NMP). Twelve discarded human livers were subjected to NMP following static cold storage. Livers were 
perfused with a packed red cell–based fluid at 37°C for 6 hours. Multilevel statistical models for repeated measures were em-
ployed to investigate the trend of perfusate blood gas profiles and vascular flow characteristics over time and the effect of lac-
tate-clearing (LC) and non-lactate-clearing (non-LC) ability of the livers. The relationship of lactate clearance capability with 
bile production and histological and molecular findings were also examined. After 2 hours of perfusion, median lactate con-
centrations were 3.0 and 14.6 mmol/L in the LC and non-LC groups, respectively. LC livers produced more bile and main-
tained a stable perfusate pH and vascular flow >150 and 500 mL/minute through the hepatic artery and portal vein, respectively. 
Histology revealed discrepancies between subjectively discarded livers compared with objective findings. There were minimal 
morphological changes in the LC group, whereas non-LC livers often showed hepatocellular injury and reduced glycogen 
deposition. Adenosine triphosphate levels in the LC group increased compared with the non-LC livers. We propose composite 
viability criteria consisting of lactate clearance, pH maintenance, bile production, vascular flow patterns, and liver macroscopic 
appearance. These have been tested successfully in clinical transplantation. In conclusion, NMP allows an objective assess-
ment of liver function that may reduce the risk and permit use of currently unused high-risk livers.
Liver Transplantation 24 1453‒1469 2018 AASLD.
Received February 1, 2018; accepted May 3, 2018.
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The demand for donor organs in liver transplantation 
greatly exceeds supply, whereas the global incidence 
of end-stage liver disease continues to rise, further 
increasing demand.(1) In the United Kingdom during 
2016-2017, 19% of patients listed for liver transplanta-
tion were either removed from the waiting list (15%) or 
died (4%) within 1 year of listing.(2) Despite the increas-
ing utilization of grafts from donation after circulatory 
death (DCD) and high-risk donation after brain death 
(DBD) donors, together known as extended criteria 
donors, wait-list mortality has not decreased.(3) Their 
use is associated with a higher incidence of early post-
transplant complications such as primary nonfunction, 
early allograft dysfunction, and/or renal failure.(4-6) 
Utilization of high-risk organs remains low, with 159 
out of 1041 livers procured in the United Kingdom 
MeRGeNTAL eT AL.
Abbreviations: ALT, alanine transaminase; ATP, adenosine 
triphosphate; cDNA, complementary DNA; CI, confidence interval; 
CIT, cold ischemia time; CV, central vein; DBD, donation after brain 
death; DCD, donation after circulatory death; H & E, hematoxylin-
eosin; HBI, hypoxic brain injury; ICH, intracranial hemorrhage; ITU, 
prolonged intensive care unit stay; LC, lactate-clearing; LFT, liver 
function test; miRNA, microRNA; NA, not applicable; NHS, National 
Health Service; NIHR, National Institute for Health Research; NMP, 
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during 2016-2017 being discarded. Only 35% of all 
potential DCD livers were transplanted because of 
DCD donation failing to proceed, inconsistencies in 
interpreting donor history and laboratory results, mac-
roscopic or histological assessment, surgeon experience, 
and the transplanting center’s expertise in marginal 
organ utilization.(7-10) These largely subjective factors 
impact upon the selection process and can compromise 
patient safety by resulting in the acceptance of high-
risk marginal grafts that fail to function, or conversely 
potentially usable organs being discarded due to a per-
ceived risk of posttransplant complications.
Normothermic machine perfusion (NMP) of the 
liver is a novel technology developed to reduce ischemic 
damage and provide superior organ preservation 
 compared with static cold storage. The purported 
advantages of NMP include the following:
1. Attenuation of ischemia/reperfusion injury.
2. Assessment of liver function prior to 
transplantation.
3. Improvement of transplant logistics.
4. The potential to deliver therapeutics to recondi-
tion currently unusable livers, enabling subsequent 
transplantation.(11‒14)
The aim of this study was to develop a standardized 
protocol for NMP, allowing functional assessment of 
donor livers rejected for transplantation, and to subse-
quently propose real-time criteria that predict liver vi-
ability. Outcomes of functional assessment were then 
correlated with histopathological assessment, which is 
currently the gold standard to assess transplantability 
of extended criteria donor livers.
Patients and Methods
SoURCe oF DiSCARDeD HUMAN 
LiveRS
The study included 12 consecutively perfused livers 
offered to our team for research, regardless of cause, 
between May 2013 and June 2015. All organs were 
procured by the UK National Organ Retrieval Service, 
using standardized surgical protocols,(15) with the pri-
mary intention of clinical transplantation and were sub-
sequently declined by all UK centers. Ethical approval 
for the study was granted by the National Research 
Ethics Service Committee in London-Surrey Borders 
(reference number 13/LO/1928). Consent to use donor 
tissues for research was obtained by specialist nurses 
normothermic machine perfusion; non-LC, non-lactate-clearing; PAS, 
periodic acid-Schiff; PT, portal triad; qPCR, quantitative polymerase 
chain reaction;  SD, standard deviation; SONOP, sonification solution; 
T0, sample taken shortly after commencing the perfusion; T6, sample 
taken after 6 hours of the perfusion; VITTAL, viability testing and 
transplantation of marginal livers; WIT, warm ischemia time.
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in organ donation from the donor’s next of kin during 
consent for organ donation. All livers were preserved 
in University of Wisconsin preservation f luid and ex-
posed to a variable period of static cold storage.
NMP oF THe LiveR
The liver preparation for NMP was analogous to clin-
ical transplantation. While bathed in slushed ice, any 
redundant tissues were removed. The portal vein was 
cleaned to its bifurcation and hepatic artery dissected 
to the gastroduodenal artery. Straight and curved 
20-Fr Medos cannulae were inserted into the celiac 
trunk and portal vein, respectively. Prior to commenc-
ing NMP, livers were f lushed with 2 L of 10% dextrose 
solution at 37°C as per our unit’s transplant protocol. 
The liver was then placed into the machine’s reservoir, 
and the cannulae were primed with perfusion f luid and 
connected to the perfusion circuits. Where required, 
a wider artery, from the same donor and surplus to 
transplant requirements, was anastomosed to the ex-
isting hepatic artery to permit cannulation. NMP 
was performed using the Liver Assist device (Organ 
Assist, Groningen, the Netherlands), which provides 
dual perfusion of the hepatic arterial and portal ve-
nous systems, in a semiclosed circuit, using 2 rotatory 
pumps that produce pulsatile and nonpulsatile f lows, 
respectively.
The initial pressure settings of 30 mm Hg for the 
artery and 8 mm Hg for the portal vein were increased 
to 50 and 10 mm Hg, respectively, within 30 min-
utes of commencing NMP. The pressure was set with 
the aim to maintain stable flows with adequate liver 
perfusion. However, in situations where the flows 
(in particular in the arterial circuit) were decreasing 
the perfusion pressures were raised in attempt to 
maintain adequate perfusion. The temperature was 
initially set to 25°C and increased incrementally to 
37°C within 30 minutes. Oxygen was supplied via a 
Sechrist air/oxygen blender (S3500CP-G, Inspiration 
Healthcare, Ltd., Leicester, UK). The fraction of 
inspired oxygen was set at 0.21 with 1 L of flow per 
minute across each oxygenator, in accordance with the 
manufacturer’s instructions. The perfusion fluid was 
based on 3 units of liver donor–specific blood group, 
Rhesus-negative, packed red cells obtained from the 
UK National Health Service Blood and Transplant. 
The constitution of the perfusion fluid is detailed in 
Table 1.
DATA AND SAMPLe CoLLeCTioN 
PRoToCoL
Flow rates, pressures, and resistances in the hepatic 
arterial and portal venous circuits were recorded every 
30 minutes. Concurrently, 2 mL of perfusate from the 
arterial and venous circuits were collected for imme-
diate blood gas analysis using the Cobas b 221 blood 
gas analyzer (Roche Diagnostics, Indianapolis, IN). If 
produced, bile was collected cumulatively and weighed 
at the end of the procedure. Liver biopsies were taken 
immediately prior to starting NMP, at 3 hours, and 
either after 6 hours or at the end of NMP, whichever 
was earlier. The tissue sample was divided and fixed 
in formalin as well as snap-frozen in liquid nitrogen. 
The summary of the sampling protocol is shown in 
Fig. 1A.
ASSeSSMeNT oF PHYSioLoGY
The perfusate from the arterial and venous outf low 
was analyzed to measure partial pressures of O2 
and CO2, pH, base excess, bicarbonate, O2 satura-
tion, hemoglobin, hematocrit, sodium, potassium, 
TABLe 1. Perfusion Fluid Constitution
Amount (Initial Bulk Fluid 
Administrated Into Reservoir)
Oxygen carrier
Packed red blood cells 3 units
Drug
Human albumin solution 5% 1000 mL
Heparin* 10,000 IU
Sodium bicarbonate 8.4%† 30 mL
Calcium gluconate 10% 10 mL
Vancomycin 500 mg
Gentamicin 60 mg
Continuous infusions
 Epoprostenol 2 μg/mL, commenced at 4 mL/hour 
and titrated as necessary
Intermittent drug administration
 Aminoplasmal 10%‡ 50 mL bolus every 6 hours
 Dextrose 10% Infusion as necessary according to 
perfusate glucose concentration
*Bolus repeated every 3 hours.
†Bolus 10-30 mL administrated if perfusate pH is <7.00 to main-
tain pH > 7.20.
‡Cernevit 2 mL and phytomenadione 1 mg (0.1 mL) added to 
Aminoplasmal 500 mL bottle.
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chloride, calcium, glucose, and lactate concentrations. 
A perfusate pH < 7.00 was corrected using 20-mL 
boluses of 8.4% sodium bicarbonate. Oxygen con-
sumption per gram of liver tissue was calculated based 
on oxygen delivery and oxygen extraction from the 
arterial and hepatic venous elements of the circuit, 
respectively. The oxygen extraction ratio was calcu-
lated as the ratio of oxygen consumption to oxygen 
delivery.
HiSToPATHoLoGiCAL 
ASSeSSMeNT
After paraffin embedding and processing, liver bi-
opsies were stained with hematoxylin-eosin (H & E) 
and periodic acid-Schiff (PAS). Biopsies were assessed 
for preexisting acute or chronic liver injury, large 
and small-droplet macrovesicular steatosis, coagula-
tive necrosis, intrahepatic bile duct injury (apoptosis, 
FiG. 1. Study design and macroscopic appearance of a viable and nonviable liver. (A) The details of the study design and the perfusate 
f luid and biopsy sampling protocol. (B) A well-perfused liver with optimal macroscopic appearance. The organ was rejected for 
transplantation due to the incidental discovery of a malignant melanoma. The liver began to function shortly after commencing the 
perfusion, and the vascular f lows and blood gas profile patterns were used to help define criteria for liver graft viability (perfusion number 
8). (C) A steatotic liver with suboptimal macroscopic appearance; this organ did not meet the viability criteria (perfusion number 2).
B
A
C
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Stac cold
storage
Preperfusion Biopsy (T0) Postperfusion Biopsy (T6)
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vacuolation, and lifting of epithelium from the base-
ment membrane), hepatocyte plate injury (hepatocyte 
loss of cohesion, detachment of hepatocyte plates from 
the sinusoidal lining), and glycogen depletion, which 
were recorded as percentages of cells affected.(16) 
Histological assessment was conducted by indepen-
dent experienced liver transplant pathologists who 
were blinded to the designated viability.
For ultrastructural examination by transmission 
electron microscopy, 2-mm biopsy pieces were fixed 
in 2.5% glutaraldehyde and processed to a resin block, 
and photomicrographs taken at ×13,000 magnifica-
tion of mitochondria within random hepatocytes and 
examined for signs of injury.(17)
ASSeSSMeNT oF ADeNoSiNe 
TRiPHoSPHATe
Measurements of adenosine triphosphate (ATP) were 
performed from snap-frozen tissue by immediate ho-
mogenization in a sonification solution (SONOP) buf-
fer (0.372 g of ethylene diamine tetraacetic acid in 130 
mL of H2O and NaOH [pH 10.9] + 370 mL of 96% 
ethanol) using the GentleMacs system. Protein con-
centration was determined using a Pierce bicinchoninic 
acid (BCA) Protein Assay kit (Thermo Scientific Inc., 
Rockford, IL). An ATP Bioluminescent Assay kit 
(FLAA, Sigma-Aldrich Inc., St. Louis, MO) was 
used to determine concentrations from a calibration 
curve on the same plate, corrected for amount of pro-
tein and expressed as nmol/g protein.
ASSeSSMeNT oF LiveR 
CeLLULAR DAMAGe BY microRNA 
ANALYSiS
The extent of the liver damage was estimated by mi-
croRNA (miRNA) 122 quantitative polymerase chain 
reaction (qPCR) analysis. RNA was isolated using 
Qiagen RNeasy kits (Eqicon, Vedbaek, Denmark) 
with the inclusion of Exiqon synthetic Spike-in tem-
plates as controls.(18) On column deoxyribonuclease di-
gestion eliminated genomic DNA. RNA samples were 
assessed on a TapeStation (Agilent Technologies, Inc., 
Santa Clara, CA) using 10-ng RNA per complemen-
tary DNA (cDNA) synthesis reaction with Exiqon 
cDNA synthesis reagents (miRCURY LNA Universal 
miRNA PCR kit) on a Labcycler (SensoQuest, 
Gottingen, Germany). Real-time PCR was per-
formed on a Roche LC480 using the miRCURY 
LNA Universal real-time miRNA PCR kit following 
reagent and protocol guidelines. Ct values were gener-
ated via the Absolute Quantitation and second deriv-
ative methods, and relative quantities were calculated.
TABLe 2. Donor Demographics and Chronology
Non-LC* LC*
Liver number 1 2 3 4 5 6 1† 2 3 4 5 6†
Donor age, years 55 55 76 60 46 71 30 69 55 57 70 50
Donor sex Female Male Female Female Male Male Male Male Male Male Female Female
BMI, kg/m2 47 33 28 36 23 30 25 31 24 25 34 45
Blood group B+ A+ O+ A+ O+ O- A+ O+ O+ A+ O+ O+
Cause of death Meningitis ICH ICH HBI ICH HBI HBI HBI Meningitis ICH HBI HBI
Donor type DBD DCD DCD DCD DBD DCD DCD DBD DBD DCD DCD DCD
Agonal period, minutes NA 14 8 17 NA 31 100 NA NA 14 16 29
Primary WIT, minutes NA 12 17 15 NA 12 12 NA NA 14 18 11
Liver weight, grams 2420 2130 1775 1712 1961 2310 1997 2400 2300 1752 1650 1943
Steatosis assessment†† Moderate Moderate Nil Moderate Mild Moderate Nil Mild Nil Mild Mild Nil
CIT, minutes 792 797 554 491 380 467 445 496 454 532 583 408
Donor risk index 1.85 2.64 3.23 2.77 1.41 3.22 1.77 1.78 1.61 2.36 3.05 2.39
Reason for discard Steatosis Steatosis CIT§ Steatosis ITU Perfusion|| WIT¶ Fibrosis Cancer Cancer CIT§ WIT¶
NOTE: Agonal period in DCD procurement was defined as the period between withdrawal of treatment to circulatory arrest. Primary 
WIT in DCD procurement designs time from circulatory arrest to in situ organ perfusion.
*The livers are grouped according the lactate metabolism (viability criteria) rather than the chronological order of the perfusion.
†Designates livers that were transplanted.
††Subjective assessment by the retrieval and/or transplant surgeon.
§Prolonged CIT.
||Poor quality liver graft perfusion.
¶Extensive WIT and CIT.
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STATiSTiCAL MeTHoDS
A total of 27 perfusion parameters were recorded over 
a 6-hour period at approximately 30-minute intervals 
(details shown in Supporting Table 1). These were plot-
ted against time, giving each liver its own observable 
trajectory, enabling trends to be visualized. Because of 
the small sample size, mean, standard deviation (SD), 
and range have been presented at initiation of NMP and 
then after 2, 4, and 6 hours of perfusion (Table 3).
The effect of lactate-clearing (LC) and non-lac-
tate-clearing (non-LC) liver status on the change 
in liver function parameters (lactate and glucose 
metabolism, pH, arterial and portal flow rates, 
hematocrit, oxygen extraction ratio, and oxygen 
consumption) were explored through multilevel lin-
ear models for repeated measures. Random intercept 
and slope effects were assigned at the liver level. 
Where linear relationships were not observed, data 
were transformed as appropriate. Explanatory vari-
ables bicarbonate, carbon dioxide, and base excess 
were adjusted for in the pH model; hepatic artery 
pressure and hepatic artery resistance were adjusted 
for in the hepatic artery flow rate model; and portal 
vein pressure and portal vein resistance were adjusted 
for in the portal vein flow rate model. An indica-
tor variable based on LC trajectories and its inter-
action with time were included in each model and 
included if found to be significant. For these explor-
atory  analyses, because the sample size is small, any 
potential interactions between lactate clearance and 
time with P value < 0.2 would be presented. Models 
were estimated using the method of maximum like-
lihood estimation and selected using likelihood ratio 
tests.
Missing data were recorded as follows: lactate 
7.7%; glucose, arterial, and portal flow rates 8.3%; pH 
11.5%; hematocrit 18.6%; and oxygen extraction ratio 
and oxygen consumption 20.5%. The used multilevel 
 models approach is tolerant of missing data under a 
missing at random assumption. Multilevel modeling 
was performed using Stata, version 14.2 (StataCorp 
LLC, College Station, TX).
The bile production, ATP, and miRNA levels were 
compared with the Mann-Whitney U test, with the 
statistical level of significance set at P < 0.05, using 
GraphPad Prism (GraphPad Software, La Jolla, CA) 
software.
Results
DoNoR DeMoGRAPHiCS, 
CHRoNoLoGY, AND ReASoNS 
FoR DiSCARDiNG LiveRS
Eight livers included in the study were from DCD 
donors. The median donor age was 56 (range, 30-76) 
years, and the median body mass index was 30 (range, 
23-47) kg/m2. The median cold ischemia time (CIT) 
was 483 (range, 380-797) minutes. Of these livers, 3 
were discarded because of steatosis, 2 for extrahepatic 
primary donor malignancy, 2 for excessive CIT, and 2 
for excessive donor warm ischemia time (WIT). The 
detailed characteristics of the included livers are pro-
vided in Table 2.
LiveR FUNCTioNAL ASSeSSMeNT
Initial graphical data explorations were performed with 
the aim of observing any trends over time. Individual 
livers’ response data were recorded for lactate, glucose, 
arterial and portal f lows, pH, oxygen extraction ratio, 
oxygen consumption, and hematocrit (Fig. 2; Table 3).
The results for lactate measurements showed 2 dis-
tinct groups; 1 had a sharp fall in lactate levels that sub-
sequently stabilized at lower levels, designated as the LC 
group, whereas the other showed fluctuations and rises in 
the lactate level over time, known as the non-LC group. 
No other response variable measured showed a similar 
performance demarcation, although the LC livers did 
appear to show similarities of behaviors when plotted.
MULTiLeveL RANDoM 
iNTeRCePT AND SLoPe MoDeLS
Results from multilevel modeling found that lactate 
levels demonstrated a significant difference in trend 
over time (P < 0.001), with LC livers being lower in 
comparison to non-LC livers.
After adjusting for bicarbonate (P < 0.001), carbon 
dioxide (P < 0.001), and excess base (P < 0.001), pH 
levels increased over time (P = 0.003), although LC liv-
ers appear to have a gentler increasing trend compared 
with non-LC livers (P = 0.10). There was a difference 
in the trend of hepatic arterial pressure over time (P 
= 0.08) with a much steeper increasing trend in the 
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FiG. 2. Multilevel random intercept and slope model findings. (A-H) Graphs illustating each liver response trajectory over time (dashed 
lines) with corresponding average trajectory predicted from the multilevel model (solid lines) for LC and non-LC livers. (A) Log-
transformed lactate levels (mmol/L): a significant difference in trend over time (P < 0.001) was observed, with LC livers being lower in 
comparison to non-LC livers. (B) The pH: on average, LC livers appear to have a gentler increasing trend compared with non-LC livers 
(P = 0.10), after adjustment for bicarbonate, carbon dioxide, and excess base. (C) Hepatic arterial pressure (mm Hg): the trends were 
different with a much steeper increasing trend in the non-LC livers (P = 0.08), after adjusting for pressure and resistance. (D) Hepatic 
artery f low (mL/minute): there appears to be a difference in trends between LC and non-LC groups (P = 0.13) after adjusting for hepatic 
arterial pressure, hepatic arterial resistance, and their interactions. (E) Portal vein pressure: an increasing trend over time (P = 0.07) was 
observed, but there was no difference between LC and non-LC livers. (F) Portal vein f low (mL/minute): portal f low increased over time 
(P = 0.13), with LC livers having a slightly higher increment in f low (P = 0.12), after adjusting for pressure and resistance. (G) Glucose 
levels (mmol/L): glucose levels decreased significantly over time (P = 0.006) and LC livers appear to have lower levels compared with 
non-LC livers. (H) Hematocrit: hematocrit demonstrated a significant reduction over time (P < 0.001) with LC livers showing a gentler 
decreasing trend (P = 0.01). (I) Oxygen extraction ratio: the levels were found not to change significantly over time, but on average, 
LC livers were 0.2 units lower than non-LC livers (P = 0.07). (J) Oxygen consumption (mL/minute/g): a significant increase in oxygen 
consumption mass over time was observed (P < 0.001); however, there appears to be no difference between LC and non-LC livers.
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non-LC livers compared with the LC livers (P = 0.08). 
Changes in arterial flow, after adjusting for arterial 
resistance (P = 0.007) and arterial pressure (P = 0.14) 
and their subsequent interaction (P = 0.01), showed a 
slightly higher increasing trend in LC livers over time 
(P = 0.13). Portal vein pressure showed an increasing 
trend over time (P = 0.07). However, there was no sig-
nificant difference between LC and non-LC livers (P = 
0.90). Portal vein flow increased over time (P = 0.13), 
with LC livers having a higher increment in flow rate 
(P = 0.12) after adjusting for portal vein pressure (P 
< 0.001), portal vein resistance (P = 0.25), and their 
interactions (P = 0.001). Glucose levels decreased sig-
nificantly over time (P = 0.006), with LC livers being 
7.8 mmol/L lower on average compared with non-LC 
livers (P = 0.15). Hematocrit demonstrated a signifi-
cant reduction over time (P < 0.001) with LC livers 
showing a gentler decreasing trend (P = 0.01). The 
oxygen extraction ratio was found not to change sig-
nificantly over time, but on average for LC livers, it was 
0.2 lower than non-LC livers (P = 0.07). A significant 
increase in oxygen consumption over time was observed 
TABLe 4. Multilevel Random effects Model Parameters examining Liver Response variables During Perfusion
Response Variables Explanatory Variables Estimate (95% CI) P Value
Lactate (log) (mmol/L)
Time (hours) 0.003 (–0.1 to 0.1) 0.96
LC indicator –0.7 (–1.2 to –0.2) 0.005
Interaction: LC indicator × time –0.3 (–0.4 to –0.2) <0.001
pH
Time (hours) 0.003 (0.001 to 0.006) 0.003
LC indicator 0.002 (–0.02 to 0.02) 0.85
Interaction: LC indicator × time –0.002 (–0.005 to 0.0004) 0.10
CHCO3 –0.05 (–0.06 to –0.05) <0.001
pCO2 –0.006 (–0.008 to –0.05) <0.001
Base excess 0.06 (0.06 to 0.06) <0.001
Hepatic artery pressure (mm Hg)
Time (hours) 2.5 (0.7 to 4.3) 0.008
LC indicator –0.6 (–14.0 to 12.8) 0.93
Interaction: LC indicator × time –2.3 (–4.9 to 0.2) 0.08
Hepatic artery flow (mL/minute)
Time (hours) 20.4 (–15.2 to 55.9) 0.26
LC indicator 51.7 (–91.6 to 195.0) 0.48
Interaction: LC indicator × time 38.0 (–10.6 to 86.6) 0.13
Hepatic artery pressure –2.3 (–5.4 to 0.8) 0.14
Hepatic artery resistance –224.9 (–387.1 to –62.7) 0.007
Interaction: pressure × resistance 3.3 (0.8 to 5.7) 0.01
Portal vein pressure (mm Hg)
Time (hours) 0.1 (–0.01 to 0.2) 0.07
LC indicator –0.06 (–1.0 to 0.9) 0.90
Portal vein flow (mL/minute)
Time (hours) 24.5 (–6.8 to 55.8) 0.13
LC indicator 48.6 (–36.9 to 134.1) 0.27
Interaction: LC indicator × time 34.9 (–8.6 to 78.5) 0.12
Portal vein pressure 163.4 (108.4 to 218.4) <0.001
Portal vein resistance 21,183.4 (–14,933.6 to 57,300.4) 0.25
Interaction: pressure × resistance –6972.7 (–11,140.1 to –2805.3) 0.001
Glucose (mmol/L)
Time (hours) –2.5 (–4.2 to –0.7) 0.006
LC indicator –7.8 (–18.3 to 2.8) 0.15
Hematocrit (%)
Time (hours) –2.5 (–3.4 to –1.6) <0.001
LC indicator –3.5 (–7.4 to 0.4) 0.08
Interaction: LC indicator × time 1.6 (0.3 to 2.8) 0.01
Oxygen extraction ratio
Time (hours) 0.0002 (–0.02 to 0.02) 0.98
LC indicator –0.2 (–0.4 to 0.01) 0.07
Oxygen consumption (mL/minute)
Time (hours) 3.8 (1.7 to 5.8) <0.001
LC indicator –1.4 (–16.5 to 13.6) 0.85
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FiG. 3. Histological findings. (A) A PAS-stained section of a non-LC liver, 4 of which had the most severe large-droplet macrovesicular 
steatosis (arrow), the type of fat considered in evaluating suitability for transplantation. This was mild involving up to 15% of hepatocytes. 
The liver was turned down on macroscopic assessment of steatosis (original objective ×10). (B) A PAS-stained section of liver 1 before 
NMP with extensive small-droplet microvesicular steatosis, where hepatocyte cytoplasm contains often numerous small droplets of fat 
that do not displace the hepatocyte nuclei. Several large fat droplets are also present. This liver was turned down due to the macroscopic 
appearance of steatosis; large-droplet steatosis was mild involving only 5% of hepatocytes in the whole biopsy. It is likely that the 
small-droplet steatosis was also seen macroscopically. This is not traditionally considered in assessing a liver for transplantation and 
indicates the requirement of a liver biopsy to accurately assess the type and amount of both types of fat droplets (original objective ×10). 
(C) A H & E–stained section of LC liver 1 at 6 hours after NMP, showing a small area of coagulative necrosis where the cells become 
hypereosinophilic (arrows). This was seen to an equal extent in both viable and nonviable livers before and after NMP and was very 
mild in this series of livers. (D-F) PAS stain from LC liver 1. (H-J) Non-LC liver 4. (D and H) Both livers demonstrated marked 
glycogen depletion pre-NMP; although after NMP (E and F), the viable liver has restored its glycogen stores. (I and J) The nonviable 
liver remains significantly glycogen depleted. Bright magenta staining of the cytoplasm indicates glycogen, and pale pink staining 
indicates no glycogen (arrow; E). (J) The few darker staining hepatocytes containing some glycogen are indicated (D, E, H, I, original 
objective ×2; F, J, original objective ×20). (G) A LC liver 3 after 6 hours of NMP, revealing normal hepatocyte plate morphology and 
attachment of hepatocyte plates to the CV. (K) Non-LC liver number 3 showing loss of cohesion of hepatocytes from each other and 
from the sinusoidal lining (arrows) and the CV 6 hours after NMP. (L and M) H & E–stained sections of non-LC liver 5, which 
was turned down for transplantation based on its macroscopic appearance. This liver had (L) portal hepatitis and (M) severe zone 3 
cholestasis (inset—high power of bile plug, arrow; original objective ×20 for both). (N) H & E–stained section of LC liver 2 discarded 
because macroscopically thought to have fibrosis. There is no fibrosis present. There is a normal portal triad (PT) showing no fibrous 
expansion. The abnormality present is centered around the CV consisting of confluent areas of hepatocyte loss in which there is variable 
hemorrhage/congestion (red color of red blood cells seen) and pigment laden macrophages (original objective ×10).
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(P < 0.001). However, there appears to be no difference 
between LC and non-LC livers (P = 0.85). The multi-
level model parameters are provided in Table 4.
BiLe PRoDUCTioN
There were significant differences in cumulative 
bile production between LC and non-LC groups. 
There was more sustained bile production in the LC 
group, although this only occurred in 4 livers. In 
the non-LC group, only 1 liver produced bile at the 
end of the NMP (2.6 g at 6 hours). After 6 hours, 
the median bile production for LC and non-LC 
groups was 6.5 versus 0.0 g (P = 0.03), respectively.
HiSToLoGiCAL FiNDiNGS
There was a significant discrepancy between the subjec-
tive assessment of liver quality performed by the organ 
retrieval or transplant surgeon and the subsequent his-
tological findings. Microscopic evaluation confirmed 
only mild large-droplet macrovesicular steatosis in livers 
declined for steatosis. Histology did not reveal any fi-
brosis in the liver declined for this presumed diagnosis.
None of the livers displayed significant large-droplet 
steatosis and at most showed only a mild degree (max-
imum of 15%; Fig. 3A). Small-droplet macrovesicular 
steatosis was greater in the non-LC livers (Table 5; 
Fig. 3B). Ischemic-type coagulative necrosis was min-
imal across both groups (Fig. 3C). Lost cohesion of 
hepatocytes, predominantly in zone 3, was observed in 
the non-LC group (Fig. 3K) with all post-NMP livers 
showing variable amounts of hepatocyte detachment 
(LC 1.5% [0%-10%] versus non-LC 15% [1%-40%]).
There was no difference in amount of glycogen deple-
tion before NMP between the groups (Fig. 3D,H; LC 
80% depletion, 5%-95% versus nonviable 75% depletion, 
5%-99%). At the end of the perfusion, the LC group 
displayed increased PAS staining (Fig. 3E versus Fig. 3I; 
LC 22.5% glycogen depletion, 5%-80% versus non-LC 
80% depletion, 10%-90%), indicating that viable livers 
were able to uptake glucose and store this as glycogen 
(Fig. 3F) or maintain glycogen stores if initially high.
The intrahepatic bile ducts displayed greater injury, 
in particular apoptosis of biliary epithelial cells, in 
the non-LC group (median of 1 versus 0) compared 
with the  LC group. Detailed histological findings are 
shown in Table 5.
The ultrastructural assessment by transmission elec-
tron micrograph demonstrated the mitochondria were 
not swollen in either liver group. However, flocculent 
densities, a sign of irreversible cell injury, were present 
in many mitochondria in the non-LC livers but were 
not present in the LC livers (Fig. 4).
ATP FiNDiNGS
The ATP analysis was performed from 8 livers, 
showing nonsignificant differences between median 
preperfusion levels (54.6 versus 15.8 nmol/g; P = 0.42), 
followed by a trend for increasement in the LC livers 
at 6 hours, contrasting with reduced ATP levels in the 
non-LC group (334.6 versus 11.9 nmol/g; P = 0.18). 
Details are shown in Table 6.
ASSeSSMeNT oF LiveR 
CeLLULAR DAMAGe BY miRNA 
ANALYSiS
For the purpose of the assay, Sp6 was used as the inter-
plate calibrator and Sp4 as the internal amplification 
control. Outliers with Ct values >37 were excluded. 
The samples were normalized to the reference gene 
miRNA-23b, converted to relative quantities and a log 
scale. Preprocessed normalized data did not reveal any 
difference between LC and non-LC livers (U value of 
39; P = 0.25).
viABiLiTY ASSeSSMeNT 
CRiTeRiA
Two livers were declined for unexpected malignancy 
confirmed in other organs after the retrieval. These 
2 livers had a favorable macroscopic appearance 
(Fig. 1B) and donor characteristics, and during NMP, 
they demonstrated properties expected of livers after 
transplant, enabling us to propose perfusion parame-
ters associated with functioning livers.
The ability of livers to clear lactate appeared to be 
a substantial marker to divide the livers into 2 groups. 
Bile production was closely related to lactate clear-
ance. However, its negative predictive value was low.
In defining clinically usable viability criteria to 
assess the function of high-risk and/or discarded liv-
ers, our main objective was to ensure transplant recip-
ient safety. We designed a composite viability measure 
consisting of lactate clearance and/or bile production 
(major criteria), in combination with additional minor 
criteria of stable arterial and portal flows, perfusate 
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pH, and favorable macroscopic assessment by the 
transplant surgeon (Table 6; Fig. 2).
Discussion
NMP has been developed to overcome shortcomings 
and organ damage occurring during static cold stor-
age. Preserving the liver in near-physiological con-
ditions at normothermia, with oxygen and nutrients, 
allows for ex vivo functional assessment. Our key ob-
jective when commencing the NMP program was to 
develop a protocol to evaluate liver function and define 
criteria characteristic of a viable liver with a view to 
preventing primary nonfunction while using high-risk 
extended criteria organs. This research, performed on 
discarded donor livers that had been exposed to a vari-
able period of static cold storage, assumed that during 
NMP potentially transplantable livers would behave 
similarly to an allograft following its implantation. 
Two livers in the study had, barring incidental donor 
malignancy, otherwise favorable donor characteristics 
and macroscopic appearances, with NMP commenc-
ing after a short duration of CIT. Provided favorable 
FiG. 4. Transmission electron micrographs and ATP and miRNA analyses. (A) shows a LC, viable liver number 4, and (B) a non-LC 
liver number 6. Both microphotographs were taken from postperfusion (T6) biopsy samples. In the nonviable liver, f locculent densities 
can be seen within several of the mitochondria (white arrows), which indicate irreversible cell injury. Christae are still apparent within 
other mitochondria and within the viable liver (A) in which no f locculent densities were observed. The mitochondria of both livers 
are not swollen (original magnification ×13,000). (C) Preperfusion and postperfusion ATP levels, showing increase in the LC livers 
contrasting with minimal change observed in non-LC livers. (D) MiRNA assays to assess the extent of cellular damage. This analysis 
did not reveal any difference between LC and non-LC groups.
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perfusion characteristics had been observed, if post-
procurement biopsies from the suspicious donor tissues 
had not shown malignancy, these organs could have 
been transplanted. The demonstrated perfusion char-
acteristics and metabolic activity in these 2 livers were 
similarly observed in 4 other livers. The most striking 
functional indicator in these 6 livers was their ability to 
metabolize lactate to near physiological levels within 2 
hours of NMP, a quality not seen in the other 6 high-
risk livers. This LC group was expected to consist of 
viable, transplantable livers. The remaining 6 non-LC 
livers were deemed nonviable. A more detailed analy-
sis of the liver perfusion characteristics showed livers 
that metabolized lactate were more likely to maintain 
a physiological pH without intervention, establish 
physiological f low rates in both the hepatic artery and 
portal vein, and have a less declining hematocrit. We 
also added evidence of bile production because this 
is generally accepted as a favorable indicator of graft 
function, although its absence is not proof of nonfunc-
tion. Using a composite of these parameters was aimed 
at maximizing patient safety.
The present study reveals unique data and novel 
observations. These are the first criteria to be suc-
cessfully tested in clinical practice and subsequently 
adopted within a clinical study of viability testing 
and transplantation of discarded human livers.(12) 
The criteria are easy to measure and consist of famil-
iar parameters. Lactate concentration is an important 
indicator of graft function in the peritransplantation 
period, and as such, its inclusion facilitated clinical 
adoption of the protocol.(19) This is the first report that 
includes marginal organs that were so severely damaged 
that we were unable to maintain the perfusion for 6 
hours, which has enabled us to assess the full spectrum 
of liver function. The proposed criteria appear to cor-
relate closely with the current gold standard assessment 
of liver transplantability: histopathological assessment. 
We have demonstrated the quite marked variability in 
the assessment of steatosis by the retrieving or trans-
planting surgeon and the histology of the liver. In this 
era of progressive organ shortage, such inconsistency 
may contribute to the waste of potentially usable livers, 
further highlighting the urgent need to develop objec-
tive assessment methods to improve the relatively low 
utilization of high-risk organs.
The Groningen group was the first to demonstrate 
the feasibility of NMP on 4 discarded human livers. 
The livers were subjected to 6 hours of NMP following 
a median CIT of 6 hours 55 minutes, with all organs 
showing recovery of function and being deemed via-
ble.(20) The inferior outcomes of some livers from our 
series may be explained in part by the CIT being on 
average 2 hours longer. A subsequent study from the 
TABLe 6. Liver Perfusion Parameters and Proposed viability Criteria
Non-LC LC
Liver number 1 2 3 4 5 6 1* 2 3 4 5 6*
Perfusion time (minutes) 541 192 501 1102 738 394 393 277 378 403 388 316
Lactate T0 (mmol/L) >20.0 13.4 13.0 13.3 7.2 15.2 7.6 9.4 12.9 13.9 13.9 5.5
Lactate T2 (mmol/L) 19.2 16.4 20.0 12.5 4.4 15.1 1.2 4.6 0.6 5.5 3.2 3.0
Trough lactate (mmol/L) 12.8 13.4 13.0 8.8 4.4 6.9 0.7 2.1 0.6 1.2 0.8 1.4
Bile production T6 (grams) 0.0 0.0 0.0 0.0 2.6 0.0 23.0 6.1 10.4 0.0 6.9 0
ATP T0 (nmol/g protein)† 15.8 — 12.1 0.0 24.6 74.7 — — 54.6 88.1 0.0 —
ATP T6 (nmol/g protein)† 46.6 — 0.6 11.5 11.9 512.8 — — 334.6 1001.9 93.5 —
ALT (IU/L)† T0 — — 4055 — — 2888 — — 574 — 2603 3673
ALT (IU/L)† peak value — 5017 1498 10,772 3803 6851
Major criteria: Trough lactate level of <2.5 mmol/L Presence of bile production
Minor criteria: Perfusate pH of >7.30 Stable arterial flow of more than 150 mL/minute and portal flow more than 500 mL/minute Homogeneous liver 
 perfusion with soft consistency of the parenchyma
NOTE: A viable liver graft has to meet ≥1 major and ≥2 of the minor criteria. All parameters are assessed 120 minutes after commenc-
ing the perfusion. To ensure recipient safety and to minimize risks of presence of a preexisting liver dis-ease or irreparable liver damage, 
only organs meeting the following criteria were considered for the pilot clinical transplant series: maximum donor age of 70 years, CITs 
of <16 hours for livers from donors after brain death, or <10 hours from DCD, donor WIT (systolic blood pressure <50 mm Hg to 
aortic perfusion) in DCD organs <60 minutes, absence of hepatitis B, hepatitis C, or human immunodeficiency virus infection, and 
healthy macroscopic appearance without signs of fibrosis or cirrhosis (Mergental et al. 2017).
*Designates livers that were transplanted.
†Values designated with “—” are missing.
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Groningen group reported an NMP series on 12 dis-
carded livers, proposing 6 hours of cumulative bile pro-
duction >20 g as a marker of good liver function.(21) 
We were unable to define a cutoff volume because 
some viable organs in our series did not produce bile. 
We concur with the observation reported by Sutton 
et al. of significantly lower lactate levels in the livers 
with a high bile output.
The Cambridge group advocated assessment based 
on perfusate transaminases and bile pH.(14) The authors 
observed a significant correlation between the alanine 
transaminase (ALT) in the perfusate measured after 2 
hours’ perfusion and the peak ALT posttransplant lev-
els within the first week.(14) They also hypothesized that 
the liver’s capacity to produce an alkaline bile (pH > 7.4) 
might be a good marker of cholangiocyte function, pos-
sibly identifying a selection of organs with a low risk 
of developing ischemic-type biliary lesions. If validated, 
this observation might revolutionize DCD liver utiliza-
tion. However, issues with bile collection, such as tech-
nical problems with bile duct cannulation, could lead to 
discarding usable livers. We agree with findings from 
the Cleveland group that the importance of bile produc-
tion in the context of NMP is possibly overestimated.(22)
NMP provides the opportunity to explore multi-
ple parameters, and it is still to be determined which 
can best predict posttransplant outcomes. We antici-
pate that future assessment methods will include more 
sophisticated techniques, including perfusate pro-
teomic and metabolomic profiling to identify sensitive 
biomarkers, which could be used in conjunction with 
the proposed viability criteria to provide further objec-
tive measurement of liver functional integrity.(23‒26) In 
this study, we also present the outcome of miRNA122 
quantitation, frequently used as a marker of tissue 
injury. The assay system we developed was technically 
robust and well validated. We identified and used an 
appropriate control miRNA and included positive 
(spiked) controls. We were unable to show a differ-
ence in miRNA122 levels between the livers defined 
viable (LC) or nonviable (non-LC). This suggests that 
although miRNA122 may correlate with the degree of 
tissue damage, it would not appear to be of value in the 
determination of liver function according to our pro-
posed criteria.
Lactate is the intermediate metabolite of pyruvate 
within the glycolysis metabolic pathway. In NMP, 
hyperlactatemia is predominantly due to relative 
tissue hypoxia resulting from impaired liver blood 
flow and decreased gluconeogenesis. In this setting, 
lactate production may exceed its clearance and may 
be an indicator for real-time liver function monitoring. 
Viability assessment based principally on lactate clear-
ance offers several advantages compared with other 
proposed markers: lactate clearance can be measured 
30-90 minutes earlier than bile production, providing 
a particular advantage when using machines designed 
for relatively short perfusions; lactate can be measured 
sequentially, providing a trend, and the rate of decline 
in lactate concentration adjusted for mass of liver tissue 
(lactate/g) may be an even better parameter for char-
acterizing the metabolic capacity of the liver compared 
with simple cutoff levels. This aspect is under active 
investigation by our group.
The comprehensive histopathological assessment 
reflected differences between the livers that were 
consistent with the grouping based on lactate clear-
ance. The development of subtle zone 3 changes 
to hepatocytes/hepatocyte plates with loss of cell 
adhesion between them and loss of contact with the 
sinusoidal lining, features reminiscent of autolytic 
changes seen at postmortem, suggest that this is an 
ischemic injury modified by lack of tissue response. 
Hepatocyte glycogen stained by PAS was maintained 
at higher levels or increased in the LC compared 
with the non-LC livers over the course of the per-
fusion, suggesting increased glycogen replenishment. 
Small-droplet microvesicular steatosis has been seen 
to develop during cold storage and subsequently fol-
lowing reperfusion, suggesting that this may also be 
a response to ischemia/reperfusion injury.(16) Taken 
together, these results support our hypothesis and 
suggest that grouping these discarded livers into via-
ble and nonviable groups according to objective func-
tional parameters has merit.
In implementing this novel strategy into our organ 
selection pathway, patient safety was the highest prior-
ity. We set an initial target of meeting criteria within 
2 hours of starting NMP. We appreciate that some 
“nonviable” organs according to the proposed criteria 
may still be salvaged by delaying the cutoff for viability 
assessment or by increasing the required lactate value. 
Whether livers from a “gray zone” of organs achieving 
lactate levels of 2.5-4 mmol/L later can be used, or if 
supplementary therapeutic interventions might allow 
safe transplantation of these organs is an important 
area of ongoing research.(27)
A limitation of our findings is incomplete per-
fusate transaminases and their correlation with the 
lactate measurements. Transaminase concentrations 
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have often been used as a surrogate marker of hepatic 
injury related to the machine perfusion procedure 
and transplantation.(11,28) Because of progressive per-
fusate hemolysis during NMP, we were only able to 
obtain complete sets of perfusate transaminases from 
4 perfusions (8, 10, 11, and 12). In each, there was a 
steady increase in ALT over the course of the 6-hour 
perfusion (6851 IU in the liver that was successfully 
transplanted). Currently, we are unable to comment 
whether transaminase levels might be used as a reli-
able indicator of liver function or if they represent a 
snapshot of the extent of cellular injury that occurred 
prior to commencing NMP. Another limitation of the 
proposed criteria is that the primary focus is on func-
tion during the early posttransplant period, aiming to 
prevent early allograft dysfunction and primary non-
function, but they do not provide any information con-
cerning the likely longterm posttransplant outcome. 
We were unable to provide robust data regarding bile 
duct condition that could be compared in the context 
of the Groningen and Cambridge groups’ dedicated 
research on ischemic cholangiopathy.(29,30)
The use of high-risk organs remains globally low, 
with the principal reasons for rejecting livers being 
steatosis, poor organ flushing, and prolonged CITs. 
Although this proportion may differ between coun-
tries, these indications clearly imply clinicians’ fear of 
primary nonfunction. Ischemic cholangiopathy as a 
rationale for liver discard would be pertinent only to 
DCD donors, particularly for those with prolonged 
WITs. For DBD livers, however, the risk of develop-
ing cholangiopathy is insignificantly low.(9) We believe 
the proposed criteria, focused primarily on the risk of 
primay nonfunction, might globally increase the utili-
zation of currently wasted livers.
The proposed criteria are, to our knowledge, the 
first to be used successfully to select and transplant via-
ble livers from the current pool of unused organs.(12,31) 
Having used these for over 3 years, we gained experi-
ence and developed confidence in the viability crite-
ria, allowing us to progress to transplanting a subset of 
these originally discarded livers successfully.
These criteria were tested in a clinical pilot pub-
lished previously, and all patients included in that 
series are well, with normal liver function and to date 3 
years or longer of follow-up. With our increased expe-
rience, we now believe the proposed criteria, used as a 
starting point for our subsequent work, including the 
VITTAL study, are conservative and can be further 
refined.(32)
In summary, this study introduces a composite of 
viability criteria including lactate concentration, bile 
production, and vascular flow patterns. The intro-
duction of objective, real-time methods of assessment 
are urgently required to address the underutilization 
of high-risk livers. NMP may lead to considerable 
expansion of the donor pool available for transplan-
tation. Although an assessment of viability is import-
ant to prevent early posttransplant graft failure, the 
effects on longterm transplant outcomes are yet to be 
determined.
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